Authentix, Inc. Signs Ten-Year Contract with Botswana Unified Revenue Service to Provide Marketplace Governance Program for Digital Marking and Tracking of Tobacco and Alcohol Products

ADDISON, Texas and GABORONE, Botswana, Aug. 2, 2022 /PRNewswire/ — Authentix announced today it has signed a 10-year contract with the Botswana Unified Revenue Service (BURS) for a fiscal marking and digital tracking solution for tobacco and alcohol products sold in the country.  This digital tax stamp program is aimed at preventing illicit trade and counterfeits while also ensuring that citizens receive genuine and safe products.

The new digital track and trace system will boost tax revenue collections levied on manufacturers and importers by increasing industry compliance, reducing illicit trade, and preventing the underreporting of volumes.  The new contract covers the marking and digital tracking of an estimated 500 million product units per year.

Authentix TransAct™, a secure SaaS-based IT data platform, along with direct printing of secure, serialized digital product codes will combine to form the industry’s leading high security digital tracking and enforcement solution.  The system will reduce and deter fraudulent activities – protecting the public from the harmful effects of contraband and ensuring a level playing field for all legitimate industry stakeholders. The countrywide program will encompass implementation, training, technical support, hardware installation, ongoing maintenance, and program management provided by the Authentix-Botswana Operations Office.

Kevin McKenna, Chief Executive Officer of Authentix, commented “We are delighted that BURS selected and trusted us to implement and manage the country’s first and very important digital tracking solution for these products.  We look forward to working with BURS and implementing the program to help quickly realize the many benefits for the citizens of Botswana.”

Collaborating with governments around the globe, Authentix Marketplace Governance programs have helped ensure the authentication and traceability of products while recovering billions of dollars in tax revenue.

About Authentix:

As the authority in authentication solutions, Authentix thrives in supply chain complexity. Authentix provides advanced authentication solutions for governments, central banks, and commercial products, ensuring local economies grow, banknote security remains intact, and commercial products have greater market opportunities. The Authentix partnership approach and proven sector expertise inspires innovation, helping customers mitigate risks, grow revenue, and gain competitive advantage.  Headquartered in Addison, Texas USA, Authentix, Inc. has offices in the US, UK, Saudi Arabia, Asia, and Africa serving clients worldwide. For more information, visit https://www.authentix.com. Authentix® is a registered trademark of Authentix, Inc.

Logo – https://mma.prnewswire.com/media/429526/Authentix_Logo.jpg

NYI étend ses opérations du 60 Hudson Street

L’acquisition de l’installation Equinix NY8 apporte une capacité de centre de données supplémentaire et un accès rentable à un vaste écosystème d’opérateurs à New York

60 Hudson Street, New York

Centre mondial d’interconnexion

NEW YORK, 02 août 2022 (GLOBE NEWSWIRE) — NYI, l’un des principaux fournisseurs de solutions d’infrastructure hybride et de services gérés, a étendu ses activités du 60 Hudson Street grâce à l’ajout d’espace précédemment occupé par Equinix. Cette expansion est le résultat d’une coentreprise avec QTD Systems, qui a acquis l’espace Equinix dans le cadre d’une transaction conclue le 1er août 2022.

Grâce à cette intégration, NYI double son nombre de centres de données et élargit immédiatement l’écosystème des opérateurs mis à la disposition des clients. L’expansion inclut également une infrastructure de conduit supplémentaire significative et un accès à l’alimentation électrique par Ethernet (PoE), qui fourniront une capacité et une portée inégalées dans l’immeuble le plus connecté de New York. Avec les capacités déjà présentes dans l’immeuble de NYI, les clients auront désormais accès à des niveaux de résilience inégalés lorsqu’ils déploieront leur stratégie d’interconnexion.

« Avec l’accélération de la transformation numérique, le rôle de 60 Hudson Street en tant que lieu prééminent pour les opérateurs mondiaux de la ville de New York devient inestimable. Il permettra de satisfaire les besoins croissants en matière de connectivité des clients », a déclaré Phillip Koblence, cofondateur et directeur des opérations de NYI. « Grâce à cette intégration, NYI augmente sa capacité à servir d’intermédiaire de premier plan pour l’accès à cette passerelle d’interconnexion mondiale, tout en rendant les déploiements à 60 Hudson Street plus simples et plus rentables. »

« J’ai une longue carrière chez 60 Hudson Street, où j’ai créé au cours des vingt dernières années plusieurs entreprises de centres de données et de connectivité qui sont toujours opérationnelles. Je me réjouis de voir NYI continuer à fournir des services de qualité et à s’appuyer sur l’infrastructure 60 Hudson NY8 d’Equinix pour booster l’avenir de l’interconnexion », a ajouté Peter Feldman, PDG de QTD Systems.

L’expansion bénéficiera à plusieurs parties :

  • Les anciens clients d’Equinix profiteront d’une continuité opérationnelle et d’un accès au personnel technique expert sur site de NYI, à la plateforme d’interconnexion rentable et à la suite de solutions d’infrastructure hybrides et de services gérés interactifs.
  • Les clients nationaux et internationaux auront accès à davantage d’espace et d’énergie, ainsi qu’à un écosystème d’opérateurs élargi.
  • Les fournisseurs et opérateurs de télécommunications bénéficieront d’un accès transparent et rentable à l’infrastructure étendue de conduit dans l’immeuble de NYI et à d’autres points d’entrée.

Grâce à des capacités étendues et à un engagement continu à réduire la complexité et à fournir une expérience client fluide, NYI espère proposer une situation équitable, rendant l’interconnexion à 60 Hudson Street plus simple et plus accessible du point de vue du déploiement et des coûts, pour les opérateurs, les fournisseurs de contenu et les entreprises de toutes tailles.

À propos de NYI

NYI est un fournisseur de premier plan de solutions hybrides d’infrastructure, de réseau et d’interconnexion. La société est connue pour réduire la complexité du paysage informatique et faciliter les solutions personnalisées afin de répondre aux besoins critiques des clients de tous les secteurs en matière d’infrastructure et de connectivité. NYI a son siège social à New York et fournit des services d’entreprise sur des marchés mondiaux clés grâce à un écosystème de partenaires de confiance. Pour en savoir plus sur NYI, rendez-vous sur nyi.net ou suivez NYI sur Twitter ou LinkedIn.

Contact auprès des médias :
Iromie Weeramantry, vice-président du Marketing
marketing@nyi.net

À propos de QTD Systems

Peter Feldman, PDG de QTD Systems, possède plus de 25 ans d’expérience dans le développement, les opérations, la gestion et la conception de centres de données, y compris la création de deux entreprises de longue date à 60 Hudson Street à New York, à savoir Telx (maintenant Digital Realty Trust) et DataGryd (maintenant Hudson IX). Il a également cofondé Digital Crossroads à Hammond, dans l’Indiana. QTD Systems se concentrera sur le développement de la prochaine génération de technologies Quantum en partenariat avec Novum Industria, une société dérivée, ou spinoff, du MIT et membre de Quantum Economic Development Corp (QED-C) dans l’ancienne installation de NY8.

Une photo accompagnant cette annonce est disponible à l’adresse https://www.globenewswire.com/NewsRoom/AttachmentNg/0cab232c-0c8d-4915-9d67-15f658bcef3b/fr

The Rockefeller Foundation Launches the Vaccination Action Network to Strengthen Health Systems and Scale Up Covid-19 Vaccinations in sub-Saharan Africa

Amref Health Africa selected as implementing partner to provide technical assistance for the new peer-to-peer learning network

NAIROBI, Kenya, August 2, 2022 /PRNewswire/ — The Rockefeller Foundation announces the launch of the Vaccination Action Network (VAN), a USD$7.4 million locally-led, peer-to-peer learning initiative designed to engage public health decision-makers across sub-Saharan Africa and bolster their efforts to strengthen health systems while scaling up Covid-19 vaccine demand strategies. Sabin Vaccine Institute and Dalberg are the secretariat for the network, while Amref Health Africa (Amref) is playing a key role to guide and administer subgrants to local organizations in participating countries so that they can implement vaccine demand generation strategies discussed during the learning sessions.

The network is already connecting ministry of health officials, implementing partners, and other key actors across Kenya, Malawi, Tanzania, and Uganda through activities designed to take place within and between countries (intra- and cross-country), so participants can share lessons learned and best practices for boosting local demand for Covid-19 vaccines. Plans to expand to other countries in the region are underway as well.

“The Vaccination Action Network’s community-based approach brings together our counterparts from across the region and country. This collaboration is the key to finding and implementing the right vaccination approach,” said Dr. Diana Atwine, Permanent Secretary, Ministry of Health, Uganda. In a recent VAN learning session focused on Wakiso district, Dr. Mathias Lugoloobi, District Health Officer in Uganda’s central Wakiso District echoed this sentiment, saying that “for strategies to be successful, the community alone must have the final say.”

While more than 60 percent of people have been fully vaccinated against Covid-19 globally, just 20 percent of people in Africa have received full doses. Inconsistent and inequitable access to supplies initially hindered the continent’s vaccination campaigns. However, uptake is now primarily impacted by complex delivery scenarios, limited access to vaccination centers, and other ongoing demand barriers, such as vaccine hesitancy and waning concerns about Covid-19 infection.

VAN’s objective is to help decision-makers understand the drivers behind vaccination and support initiatives that will increase Covid-19 vaccine uptake, while strengthening routine immunization so that health systems are better equipped to respond when the next pandemic strikes. This reflects The Rockefeller Foundation’s regional commitment to support localized solutions, empower community representatives, and create more resilient health systems.

“The Vaccination Action Network is helping to establish new channels of communication that will consistently elevate regional learnings, solutions, and leadership,” said William Asiko, Vice President of The Rockefeller Foundation Africa Regional Office. “By making these discussions country-led, we want to create a space where those directly involved in vaccination campaigns are able to voice what is working, what isn’t, and what needs to change to improve vaccination rates.”

Peer-to-peer learning is an important tool for officials who are working to address these challenges. Since the start of the Covid-19 pandemic, this type of intra- and inter-country coordination has helped the continent scale up genomic sequencing and secure essential tools, including personal protective equipment and diagnostic tests.

“By encouraging officials to come together, the Vaccination Action Network is opening new dialogues that emphasize regional solutions to local challenges,” said Githinji Gitahi, Group CEO at Amref. “This is essential to tackle vaccine equity issues, which are tied to national and regional contexts, but also offers countries an opportunity for longer-term coordination on other priorities.”

VAN will host monthly intra-country sessions and multiple cross-country discussions before the end of the calendar year, with the goal of turning learnings from these sessions into actionable solutions. To facilitate this, VAN is supporting Amref through a USD$5 million grant to design and implement tailored strategies that better reflect local needs and address demand barriers for increased vaccine uptake.

Prior to the launch, VAN hosted two cross-country and five intra-country discussions, which have already yielded results. Following a May VAN session focused on improving vaccine understanding and uptake, the Infectious Diseases Institute (IDI) at Makerere University in Kampala, Uganda is now working to train “vaccination champions” in the Wakiso district. The goal is for champions to connect with communities about the benefits of vaccines, address their questions and concerns, and ultimately encourage vaccination through community-based strategies that have proved successful in past epidemic control settings in Uganda.

“One of our biggest takeaways from the VAN conversation was that we needed to do more to engage communities with accurate and approachable information on Covid-19 vaccines, leaning on lessons learned from other health challenges such as HIV and Ebola,” said Mohammed Lamorde, Head of Global Health Security at IDI. “That’s why our program focuses on working with trusted community members and leaders to equip them with the tools they need to encourage greater uptake of vaccines within their communities.”

VAN represents the Global Vaccination Initiative (GVI)’s first major investment in overcoming low vaccine demand in Africa. Launched in April 2022, GVI is The Rockefeller Foundation’s USD$55 million effort to support country-led efforts to fully vaccinate 90% of the most at-risk populations in Africa, Asia, Latin America, and the Caribbean over the next two years.

About The Rockefeller Foundation

The Rockefeller Foundation is a pioneering philanthropy built on collaborative partnerships at the frontiers of science, technology, and innovation to enable individuals, families, and communities to flourish. We work to promote the well-being of humanity and make opportunity universal.  Our focus is on scaling renewable energy for all, stimulating economic mobility, and ensuring equitable access to healthy and nutritious food.  For more information, sign up for our newsletter at rockefellerfoundation.org and follow us on Twitter @RockefellerFdn.

Amref Health Africa, headquartered in Kenya, is the largest Africa-based International Non-Governmental Organisation (INGO). With a focus on increasing sustainable health access, Amref runs programmes in over 35 countries in Africa, with lessons learnt over 60 years of engagement with governments, communities, and partners. Amref Health Africa also engages in programme development, fundraising, partnership, advocacy, monitoring and evaluation, and has offices in Europe and North America as well as subsidiaries: Amref Flying Doctors, Amref Enterprises and the Amref International University.

About Dalberg

Dalberg is a leading social impact advisory group that brings together strategy consulting, design thinking, big data analytics, and research to address complex social and environmental challenges. It works collaboratively with communities, institutions, governments, and corporations to develop solutions that create impact at scale. The Dalberg Group is comprised of six businesses: Dalberg Advisors, Dalberg Data Insights, Dalberg Design, Dalberg Implement, Dalberg Media, and Dalberg Research, and a not-for-profit, Dalberg Catalyst. For more information, visit www.dalberg.com.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

Africa fights Monkeypox without vaccines as death toll rises: CDC

ADDIS ABABA— The vast majority of deaths due to monkeypox have been registered on the African continent but Africa remains the only part of the world with no doses of the vaccine, according to the Africa Centers for Disease Control and Prevention.

The World Health Organisation declared monkeypox a new global health emergency after 20,000 cases were reported in 77 countries. Some 75 people have died in the 11 African countries where the disease was recorded, the acting head of the African Centre for Disease Control, Ahmed Ogwell has said.

While the disease was already present on the continent in Central and West Africa before the global spread, it was detected in Europe, North America and Asia in May 2022, as it spread.

Monkeypox on the continent was mainly spread to people via infected rodents – while in Europe and North America – people with no links to animals or recent trips to the African continent seem to be contracting the disease.

WHO has stressed that anyone can be infected with monkeypox if they are in close contact with someone with the disease or they touch contaminated clothing or sheets. However, researchers are still looking into how it is spread via skin-to-skin contact.

Both the U.S. and Europe have secured doses after a number of delays; the European Commission reported it has purchased 160,000 vaccines, while the U.S. has obtained some 800,000 doses that will soon be distributed.

Source: NAM NEWS NETWORK

Nearly 700 Migrants Crossed Channel on Monday in 2022 Record

Almost 700 migrants and asylum seekers crossed the Channel to Britain in a single day this week, a new record for the year, the UK government said Tuesday.

The latest arrivals suggest the government’s controversial policy to deport those attempting the dangerous crossing to Rwanda has so far failed to deter them.

The Defense Ministry said 696 migrants arrived on 14 small boats on Monday, the highest daily tally in 2022 and only the second time this year it has topped 600.

Large groups of people, including young children, were reportedly brought ashore at Ramsgate, on the Kent coast in southeast England, before being taken by bus to processing centers.

More than 17,000 people have arrived in the UK after crossing the Channel — one of the world’s busiest shipping lanes — in small boats so far in 2022, according to government figures.

More than 28,500 — most of them young men — arrived on British shores last year. The all-time daily record of 853 was set in November 2021.

The number of crossing fluctuates through the year, depending on weather conditions and enforcement action along the northern French coastline.

In a bid to deter the arrivals, Britain earlier this year unveiled a new policy to send those crossing for processing and permanent resettlement in Rwanda.

However, the first flight due to take off in mid-June was grounded due to legal challenges, and the policy remains stalled.

Britain has been sending France tens of millions of euros annually to help stop the boat crossings, including for extra beach patrols and equipment such as night-vision goggles.

The Times reported this week that Interior Minister Priti Patel is set to announce the latest financial deal with Paris, despite questions over the arrangement’s value for money.

It has drawn consistent criticism from some ruling Conservative MPs, with one senior lawmaker telling the newspaper that Patel was “throwing more good money after bad.”

Rishi Sunak and Liz Truss, the two Conservative rivals bidding to succeed Prime Minister Boris Johnson, have both vowed to maintain the Rwanda policy.

Source: Voice of America

AOP Health Starts Research for Leukemia Treatment

AOP Health signed an agreement with Leukos Biotech for the further development of a newly discovered chemical substance. With this agreement AOP Health expands the hemato-oncology research area even further and provides additional treatment options for certain leukemia patients in the longer term.

Agnes Kohl, Chief Business Officer, AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group

Photo credit: Studio Koekart: Natascha Unkart & Isabelle Köhler

VIENNA, Austria, Aug. 01, 2022 (GLOBE NEWSWIRE) — The AOP Health Group (AOP Health) is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria. The company focuses on research, development and global sales of innovative treatment solutions and specializes in therapies for rare diseases and intensive care. In early July, AOP Health signed an agreement with Leukos Biotech, a spin-off company founded by the Barcelona-based Josep Carreras Leukaemia Research Institute. The agreement signed by AOP Health covers the option for developments of the newly discovered chemical substance within any treatable indication, not limited to oncological or rare diseases.

Luis Ruiz-Avila, Chief Executive Officer Leukos Biotech

Copyright: Albert Mollon

Agreement sets basis for new areas of therapy

At first, AOP Health will focus on the development of treatment options for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Both are special disease types of leukemia that often start in the bone marrow. Agnes Kohl, Chief Business Officer of AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group explains: “Based on positive data, our plan is to expand the development for further orphan indications even outside of AML and MDS at a later stage. With this agreement, we may be able to broaden the portfolio within our therapeutic areas offering even more treatment options for patients.”

Development in cooperation with Leukos

As AOP Health focuses on rare, hemato-oncological cancers and has many years of experience in the development and commercialization of hemato-oncological treatments, the company will drive the further development of the substance in cooperation with Leukos based on a new mode of action. This could potentially turn into a milestone in the treatment of many blood cancer and other cancer patients. Luis Ruiz-Avila, Chief Executive Officer of Leukos Biotech: “We focus on developing new treatments for a wide variety of tumors. We were born to transform excellent science from the Josep Carreras Leukaemia Research Institute into valuable products for cancer patients in need, and this agreement is a very significant step in that direction. We are convinced that AOP Health is the right partner to turn this promising, novel mechanism of action into a clinical reality for the benefit of patients in a wide variety of unmet medical needs”.

About AOP Health

The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other – especially the patients and their families as well as also the healthcare professionals treating them.

About Leukos

Leukos Biotech, SL (Leukos) is a spin-off company from the Josep Carreras Leukaemia Research Institute incorporated in Barcelona in 2015. The company is developing new treatments and diagnostic tools for a wide variety of tumors targeting the serotonin receptor HTR1B, which antitumoral potential was first described and patented by Leukos’ founder Dr. Ruth Risueño in her laboratory at the Josep Carreras Research Institute. Leukos’ main financial support is from private and institutional investors. The main shareholders are Inveready, CDTI Innvierte and the Josep Carreras Foundation. Besides investors’ support, Leukos has received non-dilutive grants and loans from the Catalan Government, the Spanish Government and the European Union in various programs.

About the Josep Carreras Foundation

The Josep Carreras Leukaemia Foundation was established in 1988 with the intention of contributing to finding a definitive cure for this disease. Its efforts are concentrated on four basic areas: administering the Spanish Bone Marrow Donor Registry (REDMO), scientific research, carried out by the Josep Carreras Leukaemia Research Institute, patient guidance through an online patient consultation channel, and reception apartments for patients who need to undergo treatment and have to spend a long time far from home.

About the Josep Carreras Leukaemia Research Institute

The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya’s CERCA network, was established in 2010 with the aim of furthering biomedical research and personalised medicine in the field of leukaemia and other onco-hematological diseases. It is the first research centre in Europe exclusively focussed on leukaemia and malignant blood diseases, and one of the very few in the world. The Josep Carreras Institutes has three coordinated but independent scientific campuses: University of Barcelona Hospital Clínic Campus, The Catalan Institute of Oncology/Germans Trias i Pujol Campus, and the Sant Pau – Autonomous University of Barcelona (UAB) Campus

About Inveready

Inveready is a leading alternative asset manager in Spain – investing in early-stage VC, growth VC, venture debt, strategic equity in listed companies, infrastructure and private equity – providing financing solutions to companies throughout their life-cycle. Founded in 2008, Inveready counts on 200 active companies, and more than €1bn of assets under management. Inveready has been investing in companies in the Life Sciences sector since 2008. Notable investments in this vertical are Atrys Health (listed on the Spanish market), EDESA Biotech (listed on Nasdaq), AVX Pharma (sold to Aerie Biotech) and PaloBiofarma (licensing agreement with Novartis). Inveready is headquartered in San Sebastian, and has other offices in Barcelona and Madrid. It has been recognized on multiple occasions by ASCRI and Preqin for the return on its funds and transactions (For more information, visit www.inveready.com).

Mag Nina Roth, MAS
nina.roth@aop-health.com

AOP Health
Needs. Science. Trust.

AOP Orphan Pharmaceuticals GmbH
Member of the AOP Health Group

Leopold-Ungar-Platz 2, 1190 Vienna, Austria
aop-health.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/f096650f-dbfc-4165-854b-63345d24a713

https://www.globenewswire.com/NewsRoom/AttachmentNg/9aa481fe-91da-4609-8570-2e9a1012c392